Lewis, Gavin A.
Rosala-Hallas, Anna
Dodd, Susanna
Schelbert, Erik B.
Williams, Simon G.
Cunnington, Colin
McDonagh, Theresa
Miller, Christopher A.
Funding for this research was provided by:
National Institute for Health Research (CS-2015-15-003)
Article History
Received: 18 February 2022
Accepted: 20 April 2022
First Online: 5 July 2022
Declarations
:
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the NHS Health Research Authority regional ethics committee (North West – Liverpool Central, 16/NW/0717, 28th November 2016).
: Written informed consent was obtained from all individual participants included in this study.
: The investigational medicinal product was gifted by Roche Products Limited. Immunoassay testing equipment and materials were gifted by Roche Diagnostics International Limited. Roche Products Limited and Roche Diagnostics International Limited had no role in study design and were not involved in the preparation, drafting or editing of this manuscript. Roche Products Limited and Roche Diagnostics International Limited conducted a factual accuracy check of this manuscript, but any decisions to incorporate comments were made solely at the discretion of the authors. CAM has served on advisory boards for Novartis, Boehringer Ingelheim and Lilly Alliance, and AstraZeneca serves as an advisor for HAYA Therapeutics and PureTech Health and has received research support from Amicus Therapeutics, Guerbet Laboratories Limited and Univar Solutions B.V.